Market Herald logo


Be the first with the news that moves the market

Hannam & Partners, a leading independent investment bank, issued an independent research report on Psyence Group.

The report identifies the company as a first mover into the palliative care market supported by natural psilocybin production.

It notes that while Psyence has already generated revenue through its functional mushroom joint venture (Psyence Function) and production facility vertical (Psyence Production), it attributes the lion’s share of Psyence’s value to its drug discovery programme and expects a 450 per cent uplift in share price.

Psyence Group Inc. (PSYG) opened trading at C$0.10

More From The Market Herald
Resverlogix Corp. - SVP of Clinical Development, Dr. Michael Sweeney.

" Resverlogix (TSX:RVX) focuses drug development on COVID-19

Clinical development of Resverlogix’s (RVX) candidate apabetalone will remain focused on preventing and treating post-COVID-19 conditions.

" No pain, no blood: BETTER Type 2 diabetes testing is coming to market

Over the past two years, reporting on the Covid-19 pandemic has dominated media airwaves.
The Market Herald Video

" BioVaxys (CSE:BIOV) expands vaccines intellectual property portfolio

BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.

" Lumiera Health (TSXV:NHP) partners with natural health industry leader

Lumiera Health (NHP) has signed an MoU to explore a strategic partnership with one of Quebec’s leaders in the natural health industry.